TAVI Forum 14

E-mail Print

TAVI FORUM 14, was held on Friday, April 17, 2026 in Munich, Germany

Materials

pdfAgenda

Introductory Remarks

pdfWelcome and Introductions
Shilpa Mitra, Forum for Collaborative Research
Veronica Miller, Forum for Collaborative Research
Per Ljungman, Karolinska Institutet
Camille Kotton, Massachusetts General Hospital

Session I: Adenovirus Updates

ADENOCLEAR Study: Preliminary Results
Jérôme Le Goff, Université Paris Cité

pdfBrincidofovir Phase 3 Study Against AdV: ENOVIA Launched
Nkechi Azie, Symbio Pharmaceuticals Ltd

Discussion
All Meeting Participants

Session II: CMV Updates

Cytogam in the Modern Era: Investigator-Initiated Study Updates
Winston Ally, Kamada Ltd.

CMV CMI in Hematopoietic Cell Transplant
Guy Handley, UT MD Anderson Cancer Center

pdfCMV CMI in Solid Organ Transplant
Cesar Berto, University of Alabama at Birmingham

Discussion
All Meeting Participants

Session III: BK Polyomavirus Updates

AIC468: A first-in-class antiviral antisense oligonucleotide in clinical development for the treatment of BKV in kidney transplant recipients
Peter Lischka, AiCuris Anti-Infective Cures AG

VP1-Targeting Small Molecules for BK Polyomavirus: Toward Direct-Acting Antivirals with Cross-Polyomavirus Activity
Ali Munawar, Orthogon Therapeutics LLC

pdfPotravitug
Juergen Beck, Memo Therapeutics AG

pdfTAVI Forum BK Project Update: Leuven/Roche
Maarten Naesens, Leuven University Hospital

Discussion
All Meeting Participants

Session IV: Herpes Viruses Updates

pdfPritelivir, Novel Helicase Primase Inhibitor, Phase 3 Trial Results
Genovefa Papanicolaou, Memorial Sloan Kettering Cancer Center

Pritelivir, Novel Helicase Primase Inhibitor, for the treatment of refractory HSV infection: NDA Progress & Pathway to Launch
Cynthia Wat, AiCuris Anti-Infective Cures AG

Gilead’s HSV Program
Yoshihiko Murata, Gilead Sciences Inc.

Kaposi Sarcoma–Associated Herpesvirus (HHV-8) Infection in Solid Organ Transplant Recipients: State of the Art and Open Challenges
Alessandra Mularoni, ISMETT

pdfTAVI Forum HHV-6 Project Update
Per Ljungman, Karolinska Institutet

Discussion
All Meeting Participants

Session V: New Topics in Transplant and Immunocompromised Populations

pdfTabelecleucel, an allogeneic cell therapy for EBV+ PTLD: Clinical Program Update
Ruchit Parikh, Pierre-Fabre Pharmaceuticals

pdfVMS063: a novel, highly potent, half-life extended, pan-measles variant antibody
Robert Allen, Invivyd Inc.

pdfMSD’s Respiratory Virus Programs
Michael Wong, Merck & Co. Inc.

pdfThe Urgent Need for Therapeutic Innovation in Kidney Transplantation
Kevin Fowler, The Voice of the Patient

Discussion
All Meeting Participants

Concluding Remarks

Next Steps
Veronica Miller, Forum for Collaborative Research
Per Ljungman, Karolinska Institutet
Camille Kotton, Massachusetts General Hospital